405 related articles for article (PubMed ID: 15025844)
1. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.
Lufkin EG; Sarkar S; Kulkarni PM; Ciaccia AV; Siddhanti S; Stock J; Plouffe L
Curr Med Res Opin; 2004 Mar; 20(3):351-7. PubMed ID: 15025844
[TBL] [Abstract][Full Text] [Related]
2. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.
Marcus R; Wong M; Heath H; Stock JL
Endocr Rev; 2002 Feb; 23(1):16-37. PubMed ID: 11844743
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic strategies for osteoporosis].
Chapurlat R; Delmas PD
Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
[TBL] [Abstract][Full Text] [Related]
4. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Martens MG
J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic prevention of osteoporotic fractures.
Zizic TM
Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
[TBL] [Abstract][Full Text] [Related]
7. The treatment of osteoporosis. Antiresorptive therapy.
Miller PD
Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
[TBL] [Abstract][Full Text] [Related]
9. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
10. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
11. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
12. Is bone mineral density predictive of fracture risk reduction?
Cefalu CA
Curr Med Res Opin; 2004 Mar; 20(3):341-9. PubMed ID: 15025843
[TBL] [Abstract][Full Text] [Related]
13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
14. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
Gorai I;
Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
[TBL] [Abstract][Full Text] [Related]
15. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
16. A review of combination regimens for osteoporosis--prevention and treatment.
Miller E; Kalin MF
Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
[TBL] [Abstract][Full Text] [Related]
17. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic therapy for the treatment and prevention of osteoporosis.
McClung B; McClung M
Nurs Clin North Am; 2001 Sep; 36(3):433-40, viii. PubMed ID: 11532658
[TBL] [Abstract][Full Text] [Related]
19. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
[No Abstract] [Full Text] [Related]
20. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
